Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

F. Ravandi; A. Pigneux; D. J. De Angelo; E. Raffoux; J. Delaunay; X. Thomas; T. Kadia; H. Kantarjian; J. Scheuenpflug; C. Zhao; W. Guo; B. D. Smith

doi:10.1038/bcj.2015.103

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

F. Ravandi, A. Pigneux, D. J. De Angelo, E. Raffoux, J. Delaunay, X. Thomas, T. Kadia, H. Kantarjian, J. Scheuenpflug, C. Zhao, W. Guo, B. D. Smith

Leukemia

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Original language	English (US)
Article number	e375
Journal	Blood cancer journal
Volume	5
Issue number	12
DOIs	https://doi.org/10.1038/bcj.2015.103
State	Published - Dec 11 2015

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1038/bcj.2015.103

Cite this

Ravandi, F., Pigneux, A., De Angelo, D. J., Raffoux, E., Delaunay, J., Thomas, X., Kadia, T., Kantarjian, H., Scheuenpflug, J., Zhao, C., Guo, W., & Smith, B. D. (2015). Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies. Blood cancer journal, 5(12), Article e375. https://doi.org/10.1038/bcj.2015.103

Ravandi, F, Pigneux, A, De Angelo, DJ, Raffoux, E, Delaunay, J, Thomas, X, Kadia, T , Kantarjian, H, Scheuenpflug, J, Zhao, C, Guo, W & Smith, BD 2015, 'Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies', Blood cancer journal, vol. 5, no. 12, e375. https://doi.org/10.1038/bcj.2015.103

@article{ed1d5b527e5c4e1691f121d887a52d54,

title = "Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies",

author = "F. Ravandi and A. Pigneux and {De Angelo}, {D. J.} and E. Raffoux and J. Delaunay and X. Thomas and T. Kadia and H. Kantarjian and J. Scheuenpflug and C. Zhao and W. Guo and Smith, {B. D.}",

year = "2015",

month = dec,

day = "11",

doi = "10.1038/bcj.2015.103",

language = "English (US)",

volume = "5",

journal = "Blood cancer journal",

issn = "2044-5385",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

AU - Ravandi, F.

AU - Pigneux, A.

AU - De Angelo, D. J.

AU - Raffoux, E.

AU - Delaunay, J.

AU - Thomas, X.

AU - Kadia, T.

AU - Kantarjian, H.

AU - Scheuenpflug, J.

AU - Zhao, C.

AU - Guo, W.

AU - Smith, B. D.

PY - 2015/12/11

Y1 - 2015/12/11

UR - http://www.scopus.com/inward/record.url?scp=84989285188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989285188&partnerID=8YFLogxK

U2 - 10.1038/bcj.2015.103

DO - 10.1038/bcj.2015.103

M3 - Letter

C2 - 26657199

AN - SCOPUS:84989285188

SN - 2044-5385

VL - 5

JO - Blood cancer journal

JF - Blood cancer journal

IS - 12

M1 - e375

ER -

Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this